PRIME II (Second Prospective Randomized Study of Ibupamine on Mortality and Efficacy): another disappointment in heart failure therapy.
Hampton
J R
JR
D003846:Deoxyepinephrine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D015996:Survival Rate; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D018491:Dopamine Agonists; D014665:Vasodilator Agents; C023487:ibopamine; D003846:Deoxyepinephrine